Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schütz

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Transplants|June 8, 2010
Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case seriesNils Lachmann, Manuela Schütz, Klemens Budde, et al.
International Immunopharmacology|December 13, 2006
Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipientsTorsten Böhler, Manuela Schütz, Klemens Budde, et al.
Transplantation|May 29, 2004
FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytesTorsten Böhler, Johannes Waiser, Manuela Schütz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 20, 2011
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejectionJohannes Waiser, Klemens Budde, Manuela Schütz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 21, 2005
Limitations of C2 monitoring in renal transplant recipientsGunilla Einecke, Manuela Schütz, Ingrid Mai, et al.
Clinical Transplantation|November 15, 2006
FTY720 (fingolimod) in renal transplantationKlemens Budde, Manuela Schütz, Petra Glander, et al.
The Journal of Clinical Investigation|October 11, 2016
Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinomaElisabeth Naschberger, Andrea Liebl, Vera S Schellerer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Transplants|June 8, 2010
Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case seriesNils Lachmann, Manuela Schütz, Klemens Budde, et al.
International Immunopharmacology|December 13, 2006
Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipientsTorsten Böhler, Manuela Schütz, Klemens Budde, et al.
Transplantation|May 29, 2004
FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytesTorsten Böhler, Johannes Waiser, Manuela Schütz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 20, 2011
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejectionJohannes Waiser, Klemens Budde, Manuela Schütz, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 21, 2005
Limitations of C2 monitoring in renal transplant recipientsGunilla Einecke, Manuela Schütz, Ingrid Mai, et al.
Clinical Transplantation|November 15, 2006
FTY720 (fingolimod) in renal transplantationKlemens Budde, Manuela Schütz, Petra Glander, et al.
The Journal of Clinical Investigation|October 11, 2016
Matricellular protein SPARCL1 regulates tumor microenvironment-dependent endothelial cell heterogeneity in colorectal carcinomaElisabeth Naschberger, Andrea Liebl, Vera S Schellerer, et al.
Pageof 1